Recurrent aphthous ulcers (RAUs), commonly known as recurrent oral ulcers, represent the most prevalent inflammatory condition affecting the oral mucosa. Epidemiological studies estimate that between 10% and 25% of the general population experiences RAUs, with prevalence rising to as high as 50% in certain subpopulations—particularly among women, who are affected more frequently than men. The condition most commonly manifests in individuals aged 10 to 30 years. Characterized by sharply demarcated, painful ulcers that recur unpredictably, RAUs significantly impair daily function: they interfere with mastication, speech, and emotional well-being, and can substantially diminish quality of life and occupational performance.
Clinical management of RAUs follows a dual-pronged strategy: first, identifying and mitigating potential triggers—including nutritional deficiencies (e.g., iron, folate, vitamin B12, or zinc), psychological stress, hormonal fluctuations, local trauma, or immune dysregulation; and second, implementing targeted symptomatic therapy. According to evidence-based guidelines issued by the Chinese Stomatological Association’s Committee on Oral Mucosal Diseases and the Committee on Integrated Traditional and Western Medicine, topical corticosteroids remain the first-line pharmacologic intervention for active lesions due to their potent anti-inflammatory and immunomodulatory effects.
Among locally acting agents, compound chamomile–lidocaine gel (marketed as Ganmeida®) has emerged as a clinically validated option supported by both domestic and international research. Approved for use in oral mucosal ulcers—including minor RAUs—as well as herpes labialis–associated pain and trauma-induced mucosal inflammation (e.g., from ill-fitting dental prostheses), this formulation combines multiple therapeutic mechanisms in a single topical preparation.
Ganmeida® contains lidocaine for rapid surface analgesia; thymol and chamomile tincture for broad-spectrum antimicrobial activity; and chamomile tincture—rich in bisabolol and flavonoids—for its documented anti-inflammatory and wound-healing properties. Preclinical and clinical studies indicate favorable safety, with no significant systemic absorption or adverse mucosal reactions reported. Randomized clinical trials have demonstrated statistically significant reductions in ulcer pain scores, lesion size, and healing time compared with placebo or conventional topical therapies, confirming its efficacy in managing mild-to-moderate RAUs.
Complementary nonpharmacologic strategies play a critical role in long-term management. During active episodes, patients should avoid irritants such as spicy, acidic, excessively hot, or mechanically abrasive foods. Oral hygiene must be maintained gently—using a soft-bristled toothbrush and alcohol-free, low-irritant mouth rinses after meals—to prevent secondary infection and support epithelial repair. Lifestyle modifications—including consistent sleep hygiene, stress reduction, and targeted nutritional supplementation (notably B-complex vitamins and zinc)—have been associated with reduced ulcer frequency and accelerated resolution in observational and interventional studies.
Selecting an optimal topical agent for RAUs requires balancing rapid symptom control with safety, tolerability, and biologic plausibility for mucosal repair. Ganmeida® compound chamomile–lidocaine gel meets these criteria through its multimodal pharmacology and robust clinical evidence base. When integrated into a comprehensive care plan—including trigger identification, gentle oral care, and supportive lifestyle measures—it offers a practical, patient-centered approach to reducing disease burden and promoting sustained mucosal health.